Clinical Trial News and Research

RSS

Precision medicine tools offer hope for patients with rare blood cancers

Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.

9 Apr 2026

Long-term excess weight is a stronger predictor of cardiovascular risk

Obesity is a known risk factor for cardiovascular disease, but people's weights can shift over time, and little is known about the cumulative impact of excess weight.

8 Apr 2026

New monoclonal antibody shows promise for preventing Lyme disease

A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum concentrations in participants, according to data presented by Mark Klempner, MD, at the World Vaccine Congress 2026 in Washington D.C.

8 Apr 2026

Duloxetine fails to prevent nerve damage caused by chemotherapy

A randomized trial conducted by the Alliance for Clinical Trials in Oncology with support from the National Cancer Institute has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by chemotherapy in patients with colorectal cancer.

8 Apr 2026

Self-practice training improves CBT skills and reflective practice

Researchers at The University of Osaka have developed and evaluated a new eight-week training program that enables psychology trainees to effectively CBT by applying its techniques to themselves.

7 Apr 2026

Hearing loss and sex shape dual-task outcomes in older adults with mild cognitive impairment

Cognitive and physical training can help older adults with mild cognitive impairment (MCI) maintain or improve their ability to move and think simultaneously, but hearing ability and sex influence outcomes, according to a new Concordia-led study.

7 Apr 2026

Navigated TMS significantly boosts combat PTSD recovery rates

An advanced version of a procedure using magnetic fields to stimulate brain nerve cells in treating depression was significantly effective for 85% of active military and veterans suffering from combat post-traumatic stress disorder enrolled in a recent study, when added to psychotherapy.

7 Apr 2026

First participants join clinical study to fast-track dementia research in the UK

The Dementia Trials Accelerator has taken a significant step towards transforming dementia clinical trials in the UK by welcoming its first participants into clinics for simple tests that will ultimately get the right people into clinical trials quicker, speeding up vital research.

7 Apr 2026

Smartphone app HabitWorks improves anxiety and depression symptoms

In an effort to increase access to evidence-based interventions to help manage anxiety and depression, Mass General Brigham investigators have developed and tested a novel digital intervention called HabitWorks.

2 Apr 2026

State-run insurance plans for foster kids leave some of them without doctors

Ollie Super has moved in and out of cancer treatment since she was diagnosed with neuroblastoma as a toddler in foster care. Now 8, the second grader is dealing with it again. Her cancer came back late last year.

2 Apr 2026

NIH funds AI project to advance Alzheimer’s research and treatment

The National Institutes of Health has renewed support for Artificial Intelligence for Alzheimer's Disease, or AI4AD. The new $12.6 million award to advance the project's next phase, AI4AD2, brings its total investment in AI4AD to $30.7 million.

1 Apr 2026

Trial tests fast-acting brain stimulation for postpartum depression treatment

The Icahn School of Medicine at Mount Sinai today announced the enrollment of its first patient in a U.S. Department of Defense-funded pivotal clinical trial to evaluate whether a fast-acting, drug-free brain stimulation therapy can safely and quickly relieve symptoms of postpartum depression.

1 Apr 2026

Gene-edited treatment shows promising outcomes for severe sickle cell disease

New results from a clinical trial show promising outcomes for a gene-edited treatment for severe sickle cell disease, a genetic blood disorder with few curative options.

1 Apr 2026

Digital twin hearts improve outcomes in arrhythmia ablation procedures

Working with "digital twins" of patients' hearts, doctors improved cardiac ablation outcomes for patients with life-threatening arrythmias.

1 Apr 2026

Targeted therapy pralsetinib improves outcomes in RET fusion-positive NSCLCs

In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth.

1 Apr 2026

PRISM ALS: A new global collaboration to expand patient-derived stem cell models and accelerate treatments

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for testing treatments do not currently reflect the diverse nature of the disease - that affects both researchers developing therapies and the people urgently waiting for them.

From ALS Therapy Development Institute (ALS TDI) 1 Apr 2026

Lung cancer scans can reveal signs of other undiagnosed cancers

When doctors review diagnostic medical scans for lung cancer, they sometimes spot abnormalities unrelated to the lungs.

31 Mar 2026

New stem cell therapy offers permanent cure for Hirschsprung disease

Scientists are developing a revolutionary new stem cell therapy to treat a rare and life-threatening disease that leaves newborn babies unable to function without invasive surgery, thanks to a collaboration between UCL, the University of Sheffield and Queen's University Belfast.

31 Mar 2026

PSMA therapy may postpone hormone treatment in prostate cancer patients

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is also effective in an earlier stage of the disease.

30 Mar 2026

Antidepressant fluvoxamine reduces long COVID fatigue in clinical trial

A randomized placebo-controlled trial found that fluvoxamine, a low-cost antidepressant, reduced fatigue and improved quality of life in adults with long COVID, offering one of the first evidence-based medication options for this persistent condition. In contrast, metformin did not provide meaningful benefit for established long COVID fatigue, highlighting fluvoxamine as the more promising treatment candidate in this study.

30 Mar 2026